Background: Cardiac cachexia is common in people and dogs with congestive heart failure (CHF). However, the prevalence and effects of cardiac cachexia in cats are unknown.
disease. 4, 5 In people, the presence of cachexia negatively affects strength, immune function, wound healing, quality of life, and survival. 6, 7 There is continued debate in the scientific community about the optimal definition for cachexia. Currently, at least 11 definitions of cachexia and 7 definitions of sarcopenia are used in people. 2, [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] This discrepancy in definitions affects estimates of the prevalence of cachexia and sarcopenia, with 1 recent systematic review of studies in older people showing that sarcopenia prevalence ranged from 9.9% to 40.4%, depending on which definition was used. 19 In people with heart failure, prevalence rates for cardiac cachexia range from 10.5% to 42%, depending on the definition and the patient population. 7, 20, 21 In dogs, the prevalence of cardiac cachexia (based on muscle loss) is 48%-69%. 22, 23 The prevalence of cardiac cachexia in cats with CHF (based on muscle loss) was 48% in one small study. 24 Nearly all human definitions of cachexia rely on weight loss as a criterion. This reliance on weight loss for defining cachexia might delay the diagnosis of cachexia since loss of body weight might lag behind loss of muscle and meeting the criterion of weight loss might not occur until late in the underlying disease. One study of people with cancer cachexia, for example, showed that of the patients who did not meet the inclusion criterion of ≥5% weight loss over the prior 6 months, 41% had ≥5% muscle loss over the same period, suggesting that muscle loss might be a more sensitive measure of cachexia. 25 This is particularly true in cardiac cachexia where fluid accumulation can mask weight loss. Another challenge with weight loss as a criterion for the diagnosis of cachexia is that a patient might not have had a body weight measurement in the previous 6-12 months with which to compare to the current body weight. Weight loss might underestimate the prevalence and also might not identify those patients that are most negatively affected by cardiac cachexia. In people with CHF, muscle loss, and not weight loss, is associated with negative effects on strength, function, and quality of life. 26 A consistent and sensitive definition could be even more important in veterinary medicine, given the option of euthanasia which can be influenced by factors such as poor appetite, weakness, and quality of life, all common issues in cardiac cachexia. In 1 study of owners of dogs euthanized for CHF, poor quality of life, weight loss, and anorexia were common reasons cited by owners for the euthanasia decision. 27 The role of cachexia on the euthanasia decision was not assessed in that study.
The objective of this study was to compare the prevalence of cachexia in cats with CHF using the different definitions available in human and veterinary literature. The hypothesis was that using the definition of cachexia based on muscle loss via muscle condition score (MCS) would identify more cats with cardiac cachexia than other definitions.
A secondary objective was to determine clinical and laboratory differences, as well as outcomes, for cats with and without cardiac cachexia.
| METHODS

| Comparison of cachexia definitions
The hospital's electronic medical records system was searched to identify all cats with CHF due to any form of cardiomyopathy evaluated by the Cardiology Service between June 2015 and September 2018. This starting date was chosen because June 2015 was when the current electronic medical records system was instituted and when MCS began to be collected on all animals during cardiology appointments. An echocardiogram was performed on each cat (GE Vivid 7 Dimension, General Electric Healthcare, Milwaukee, Wisconsin). A board-certified cardiologist or resident under the supervision of a board-certified cardiologist obtained standard right and left parasternal echocardiographic views with standard echocardiographic measurements. 28 Cats were determined to have primary myocardial disease (cardiomyopathy) by the attending veterinarian. The diagnosis of CHF was based on the presence of pleural effusion or pulmonary edema confirmed via thoracic radiography or thoracic ultrasound with referable clinical signs, in combination with a diagnosis of cardiomyopathy based on echocardiography. Exclusion factors included cats less than 1 year of age and cats with other major concurrent diseases that could contribute to muscle loss (eg, cancer, preexisting chronic kidney disease), and cats with unregulated hyperthyroidism or systemic hypertension (systolic blood pressure > 180 mm Hg). Cats with CHF due to congenital defects or primary valvular disease, as well as cats with tachyarrhythmia-induced CHF also were excluded.
Medical records were reviewed using a standardized data form to collect the following information from the time of diagnosis of CHF: age, sex, breed, underlying type of myocardial disease, International Small Animal Cardiac Health Council (ISACHC) stage (stage 1 = asymptomatic heart disease, stage 2 = mild CHF, stage 3 = advanced CHF), 29 CBC and serum biochemistry results, body weight, body condition score (BCS; on a 9-point scale), and MCS (normal, mild, moderate, or severe muscle loss; Figure 1 ). 30 The BCS and MCS were initially recorded in the medical records by veterinary students but were reviewed and confirmed in all cases by 1 of the cardiologists or cardiology residents. Where available, body weight data from previous visits at our hospital and at primary care veterinarians' hospitals were collected to calculate percent change in weight in the 6 and 12 months before diagnosis and percent change in weight after diagnosis of CHF.
The date and cause of death, if not still alive, were also collected. If survival information was not available in the medical record, the primary care veterinarian was contacted or, if any information was still unavailable, the owner was contacted. If the owner could not be contacted, the cat was considered lost to follow-up.
Prevalence of cachexia in cats at the time of diagnosis of CHF was compared using 7 different definitions available in the human and veterinary literature that are applicable to companion animals:
1. Weight loss of at least 5% in the 12 months before diagnosis of CHF (ie, at the time of diagnosis of CHF, cats had already lost at least 5% of their body weight in the previous 12 months) + 3 of the following 5 criteria determined at the time of diagnosis: decreased muscle strength, fatigue, anorexia, low fat-free mass index, or abnormal biochemistry (anemia or low albumin). 8 Fatigue was defined as lethargy, and decreased muscle strength was defined as weakness noted by the owner.
2. At least 1 prescription for megestrol acetate, oxandrolone, somatropin, or dronabinol being taken at the time of diagnosis of CHF or after the diagnosis of CHF. 9 This definition was modified to include the following veterinary medications: cyproheptadine, mirtazapine, diazepam, or capromorelin (Entyce, Aratana Therapeutics, Leawood, Kansas).
3.
Greater than or equal to 5% weight loss occurring after the diagnosis of CHF. 9 F I G U R E 1 Muscle condition scoring system used to evaluate 125 cats with congestive heart failure. 30 Provided courtesy of the World Small Animal Veterinary Association (WSAVA). Available at the WSAVA Global Nutrition Committee Nutritional Toolkit website: https://www.wsava. org/Guidelines/Global-Nutrition-Guidelines. Accessed November 12, 2019. Copyright Tufts University, 2014 4. Weight loss greater than 5% in the 6 months before diagnosis of CHF (ie, at the time of diagnosis of CHF, cats had already lost at least 5% of their body weight in the previous 6 months). 13 5. Unintended loss of 5% or more of body weight in the 6-12 months before diagnosis of CHF (ie, at the time of diagnosis of CHF, cats had already lost at least 5% of their body weight in the previous 6-12 months). 18 6. Low BCS (<4/9) at the time of diagnosis of CHF. 15 7. Muscle loss based on MCS (ie, mild, moderate, or severe muscle loss) at the time of diagnosis of CHF. 2,30 The number of cats with sufficient information on which to determine the prevalence of cachexia based on the different definitions ranged from 18-125 (Table 1 ). Based on the 7 different definitions, the prevalence of cachexia ranged from 0.0 to 66.7% (Table 1) 
| Statistical analysis
| DISCUSSION
An important challenge in the study of all forms of cachexia is the optimal definition, which has been debated in human medicine for that it is the muscle loss that is more important for the negative effects of cachexia, rather than weight loss alone. 31, 32 In human heart failure patients, those with muscle loss had more functional deficits and reduced quality of life-whether or not they had weight losscompared to patients with weight loss alone. 31 Therefore, it is loss of muscle that has the most important clinical implications which supports its role in diagnosis. In addition, results of at least in 1 study of human patients with nonischemic DCM showed muscle loss appeared to occur earlier than weight loss so might be a more sensitive measure of the negative effects of body composition changes in heart failure. 32 Therefore, although the optimal definition of cachexia in veterinary and human medicine is not yet known, the current study compared the prevalence of multiple possible options that have been used in the literature in order to begin the conversation on best approaches for identifying cardiac cachexia in cats.
Results of this study showed a wide variation in the prevalence of cachexia in this population of cats with CHF, ranging from 0. For both definition 4 (≥5% weight loss in the 6 months before diagnosis of CHF) and definition 5 (≥5% weight loss in the 6-12 months before diagnosis of CHF), the prevalence of cachexia was similar (42.9%-45.2%). However, only 22.4%-33.6% of cats had a body weight recorded in the 6-12 months before diagnosis of CHF, so it was impossible to assess most of the cats for weight loss.
In the current study, all 125 cats had BCS (definition 6) and MCS (definition 7) recorded at the time of diagnosis of CHF. Definition 6 (BCS <4/9) yielded a low prevalence of cachexia (12.0%) and did not appear to be a good approach for identifying cachexia because few cats were actually underweight. In addition, cats in all BCS categories is similar to that reported in 1 smaller study of cats with CHF (48%) 24 and in 3 studies of dogs with varying stages of CHF (48%-54%), 22, 23, 33 although lower than 1 study which reported a prevalence of 69% in dogs with advanced heart failure due to degenerative mitral valve disease. 23 Prevalence reported in studies of human heart failure ranges from 10.5% to 42% (but is most commonly reported to be approximately 10%). 7, 20, 21 In addition, MCS focuses on the body compartment that is most affected by cachexia-muscle-rather than the surrogate of body weight which appears to be less sensitive, might be affected by fluid accumulation, and is less associated in humans with the negative effects on strength, function, and quality of life. 26 Therefore, it appears that the MCS is a good clinical method of identifying cachexia in cats.
The only requirement for using MCS to identify cachexia is that clinicians assess MCS at every visit in every cat. This does not obviate the need for also monitoring body weight and BCS at every visit. In In the current study, cats with cachexia were more likely to have pleural effusion than cats without cachexia. 8 Cats with cachexia were also older and had a significantly higher BUN concentration and BUN/creatinine ratio (but not higher creatinine). Results of a study of clinical and laboratory findings in dogs with cardiac cachexia showed no significant difference in BUN or creatinine between dogs with and without cardiac cachexia, 33 but that dogs with cachexia had a significantly higher BUN/creatinine ratio (Ineson, Freeman, and Rush, unpublished data) . This higher BUN/creatinine ratio could be the result of increased BUN, as can be seen with catabolic states or higher dietary protein intake, or to decreased creatinine concentrations, which can be the result of muscle loss (or a combination of both). 35 The higher BUN/creatinine ratio could also be due to early prerenal azotemia (eg, dehydration, diuretic use), or gastrointestinal blood loss, or could be seen in young animals. 35 The BUN/creatinine ratio has also been identified in human patients with heart failure and might reflect neurohormonal activation in heart failure. 36 Neutrophil concentrations also were significantly higher in cats with cachexia, a finding that was not found in a small, unpublished In the current study of cats, the presence of cardiac cachexia (based on MCS) was significantly associated with a shorter survival time based on all-cause mortality, as has been seen with human 6,7 and canine studies. 33 However, it is important to note that this study only showed an association between cachexia and shorter survival and did not prove [45] [46] [47] Other variables might be associated with survival time in cats with CHF, but the small sample size and retrospective nature of the study likely limited the ability to detect other significant associations.
An important limitation of this study was its retrospective nature, so not all of the measurements were available for all the cats and not all were collected at the same time points. This was especially an issue for body weight where in some cases, there were gaps of months to years between recorded body weights. Given that 4 of 7 of the definitions required multiple body weight measurements within a specific time frame, only between 15% and 59% of cats could be included in prevalence calculations using these 4 definitions. Muscle condition score is subjective so, while MCS was assessed only by clinicians on the cardiology service, there could be some interrater variation, as seen in previous studies. 14, 48 Echocardiographic measurements were not analyzed in the current study and would be valuable to include in future, larger studies to determine whether there are any relationships between cachexia, echocardiographic measurements, and outcome. In addition, it is unclear whether all of the weight and muscle loss identified at the time of diagnosis of CHF was due solely to the underlying cardiac disease and not to other diseases or to the muscle loss associated with aging (ie, sarcopenia). Cats with other major concurrent diseases that could contribute to muscle loss, such as cancer, chronic kidney disease, diabetes, or unregulated hyperthyroidism, were excluded from the study, but it is still possible that other undiagnosed disease was present.
In addition, since muscle loss (sarcopenia) occurs during aging even in the absence of disease, the weight and muscle loss in these cats at the time of diagnosis could have been related to that, rather than to the underlying cardiac disease. Further research on the time course of weight and muscle loss in cats with cardiomyopathy-both before and after the development of CHF-is warranted. Another limitation is the option for euthanasia in veterinary medicine, which impacts survival time. Finally, the small sample size limited statistical power to detect other differences between cats with and without cachexia and to detect associations between other variables and survival. Nonetheless, results of this study show that measuring muscle loss with the MCS provides the opportunity to detect cardiac cachexia in cats with CHF at a single time point, without having to rely on sequential body weights.
Using this simple clinical MCS measurement, 41.6% of cats with CHF met the definition for cardiac cachexia and, more importantly, the presence of cardiac cachexia was associated with a shorter survival time.
Further studies on potential methods to prevent and treat cardiac cachexia are warranted, as are methods for promoting the use of MCS as part of the standard physical examination. Purina PetCare (all outside the published work).
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